Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.19.2
SEGMENT INFORMATION
6 Months Ended
Apr. 30, 2019
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

9.         SEGMENT INFORMATION          


We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”).  Reportable operating segments are determined based on the management approach.  The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance.  While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) Cancer Diagnostics, (ii) Cancer Therapeutics and (iii) our legacy patent licensing activities.  The following represents selected financial information for our segments for the six and three months ended April 30, 2019 and 2018 and as of April 30, 2019 and October 31, 2018:


 

For the Six Months Ended

April 30,

 
 

 

2019

 

 

2018

Net loss:

         

Cancer Diagnostics

$

(3,052,355)

 

$

(1,362,451)

Cancer Therapeutics

 

(3,517,219)

   

(1,551,067)

Patent licensing

 

(971,969)

 

 

(344,470)

Total

$

(7,541,543)

 

$

(3,257,988)

           

Operating costs and expenses excluding non-cash

    share based compensation expense:

         

Cancer Diagnostics

$

1,417,967

 

$

1,075,480

Cancer Therapeutics

 

1,245,681

   

1,348,498

Patent licensing

 

1,091,700

 

 

1,002,879

Total

$

3,755,348

 

$

3,426,857

           

Operating costs and expenses excluding non-cash

    share based compensation expense

$

3,755,348

 

$

3,426,857

Plus non-cash share-based compensation expense

 

4,071,614

 

 

598,683

Total operating costs and expenses

$

7,826,962

 

$

4,025,540


For the Three Months Ended

April 30,

 

 

2019

 

 

2018

Net loss:

         

Cancer Diagnostics

$

(1,248,001)

 

$

(739,202)

Cancer Therapeutics

 

(1,029,934)

   

(442,049)

Patent licensing

 

(296,999)

 

 

(211,263)

Total

$

(2,574,934)

 

$

(1,392,514)

   

 

   

 

Operating costs and expenses excluding non-cash 

    share based compensation expense:

         

Cancer Diagnostics

$

658,433

 

$

549,866

Cancer Therapeutics

 

444,890

   

393,645

Patent licensing

 

418,461

 

 

875,733

Total

$

1,521,784

 

$

1,819,244

           

Operating costs and expenses excluding non-cash

    share based compensation expense

$

1,521,784

 

$

1,819,244

Plus non-cash share-based compensation expense

 

1,321,450

 

 

331,710

Total operating costs and expenses

$

2,843,234

 

$

2,150,954


           
 

  April 30,

2019

 

  October 31,

2018

   

Total assets:

         

Cancer Diagnostics

$

3,605,773

 

$

2,545,803

Cancer Therapeutics

 

2,939,717

   

2,157,359

Patent licensing

 

1,219,936

 

 

1,745,380

Total

$

7,765,426

 

$

6,448,542


Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.